Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia

Noninvasive Stool RNA Test Approximates Disease Activity in Patients With Crohn’s Disease

Analytical Validation of the Multitarget Stool RNA Test for Colorectal Cancer Screening

CRC-PREVENT: Multi-target Stool RNA Test for Colorectal Cancer Screening

Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort

Noninvasive Detection of High-Risk Adenomas Using Stool-Derived Eukaryotic RNA Sequences as Biomarkers

Development of a Second Generation Multi-Target Stool RNA Test (ColoSense 2.0) for Colorectal Cancer Screening

Stool-derived Eukaryotic RNA Assay Approximates Disease Activity Index and Predicts Therapeutic Response in Patients with Crohn’s Disease on Advanced Therapies

Stool-derived Eukaryotic RNA Biomarkers for Predicting Therapeutic Response and Monitoring Mucosal Healing for Patients with Inflammatory Bowel Disease

Cost Effectiveness Analysis of Novel RNA-Fit Test as a Strategy for CRC Screening in Average Risk U.S. Population

CRC-PREVENT: clinical validation study shows expedited and diverse recruitment for the non-invasive RNA-FIT test that can detect advanced colorectal neoplasia with high sensitivity

Prospective Study Using Virtual Enrollment to Access An RNA-FIT Assay for Non-invasive Detection of Colorectal Neoplasis